More tools:Markets·Screener·Research·Chat

NovoCure Limited Ordinary Shares (NVCR) Financial Statements

NovoCure Limited Ordinary Shares
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG009XW8QY0
XNAS · usd
16.85▼ 1.09 (-6.08%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close17.94
Day's Range16.57 – 17.78
52-Week Range9.82 – 21.45
Volume1.5M
Avg Volume1.2M
Share Statistics
Shares Outstanding
Employees1,605
ExchangeXNAS
Listed2015-10-02
Share count as of July 17, 2026
Loading Income Statement…
Key questions about NovoCure Limited Ordinary Shares (NVCR)
What is NovoCure Limited Ordinary Shares's Market Cap?
NovoCure Limited Ordinary Shares's Market Cap is $2.0B, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's Enterprise Value?
NovoCure Limited Ordinary Shares's Enterprise Value is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's Price / Sales?
NovoCure Limited Ordinary Shares's Price / Sales is 2.8×, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's EV / Revenue?
NovoCure Limited Ordinary Shares's EV / Revenue is 3.0×, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's EV / EBITDA?
NovoCure Limited Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's Revenue (TTM)?
NovoCure Limited Ordinary Shares's Revenue (TTM) is $699.2M, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's Net Income (TTM)?
NovoCure Limited Ordinary Shares's Net Income (TTM) is -$148.6M, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's EBITDA?
NovoCure Limited Ordinary Shares's EBITDA is -$138.1M, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's Diluted EPS (TTM)?
NovoCure Limited Ordinary Shares's Diluted EPS (TTM) is -1.28, based on as-reported figures from SEC (XBRL) filings.
What is NovoCure Limited Ordinary Shares's EBITDA Margin?
NovoCure Limited Ordinary Shares's EBITDA Margin is -19.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net revenues
YoY growth+15.6%+12.3%+8.1%+7.8%
Cost of revenues
Gross profit
% of revenue77.6%77.6%75.8%73.2%
Operating costs and expenses:
Research, development and clinical studies
Sales and marketing
General and administrative
Total operating costs and expenses
% of revenue83.4%116.4%99.0%94.8%
Operating income (loss)
% of revenue-5.8%-38.7%-23.2%-21.5%
Financial income (expenses), net
Income (loss) before income tax
Income tax
Net income (loss)
% of revenue-8.5%-40.9%-14.1%-22.3%
Basic net income (loss) per ordinary share (in usd per share)
Diluted net income (loss) per ordinary share (in usd per share)